West-Ward Pharmaceuticals, a wholly owned subsidiary of HikmaPharmaceuticals PLC (Hikma) has appointed Daniel Motto as executive vice president (VP) of US injectables division.
He will have responsibility for sales, marketing, commercial operations and business development. In this role, he will focus on maximizing West Ward/Hikma’s injectables R&D portfolio, building new customer relationships and expanding business development.
Motto joins Hikma from Teva Pharmaceutical Industries Ltd, where he most recently led its global business development, portfolio management, business intelligence and biosimilars businesses.
Prior to that, he served as a member of the generics leadership team that drove organic growth, formed extensive partnerships and executed multiple acquisitions, including the acquisition of Actavis and Allergan that took Watson Labs from a smaller US generic player to a top 10 global pharmaceutical company. He has also held senior roles at Sandoz and Johnson & Johnson.
West-Ward Pharmaceuticals, a wholly owned subsidiary of HikmaPharmaceuticals PLC (Hikma) has appointed Daniel Motto as executive vice president (VP) of US injectables division.
He will have responsibility for sales, marketing, commercial operations and business development. In this role, he will focus on maximizing West Ward/Hikma’s injectables R&D portfolio, building new customer relationships and expanding business development.
Motto joins Hikma from Teva Pharmaceutical Industries Ltd, where he most recently led its global business development, portfolio management, business intelligence and biosimilars businesses.
Prior to that, he served as a member of the generics leadership team that drove organic growth, formed extensive partnerships and executed multiple acquisitions, including the acquisition of Actavis and Allergan that took Watson Labs from a smaller US generic player to a top 10 global pharmaceutical company. He has also held senior roles at Sandoz and Johnson & Johnson.
No comments:
Post a Comment